A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia | Zendy

Dirk Blom | Zendy; Tomas Hala | Zendy; Michael A. Bolognese | Zendy; Michael Lillestol | Zendy; Phillip D. Toth | Zendy; Lesley Burgess | Zendy; R Češka | Zendy; Eli M. Roth | Zendy; Michael J. Koren | Zendy; Christie M. Ballantyne | Zendy; Maria Laura Monsalvo | Zendy; Kate Tsirtsonis | Zendy; Jae Bum Kim | Zendy; Robert C. Scott | Zendy; Scott M. Wasserman | Zendy; Evan A. Stein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Author(s) -

Dirk Blom,

Tomas Hala,

Michael A. Bolognese,

Michael Lillestol,

Phillip D. Toth,

Lesley Burgess,

R Češka,

Eli M. Roth,

Michael J. Koren,

Christie M. Ballantyne,

Maria Laura Monsalvo,

Kate Tsirtsonis,

Jae Bum Kim,

Robert C. Scott,

Scott M. Wasserman,

Evan A. Stein

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1316222

Subject(s) - evolocumab , medicine , pcsk9 , placebo , atorvastatin , hyperlipidemia , ezetimibe , cholesterol , clinical endpoint , endocrinology , gastroenterology , urology , randomized controlled trial , lipoprotein , diabetes mellitus , ldl receptor , alternative medicine , apolipoprotein a1 , pathology

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research